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Abstract
Background: SnoN is an important regulator of the transforming growth factor beta (TGFβ)
signalling pathway and has been shown to exhibit both tumour promotion and suppression activity.
Methods: To further explore the role of this complex molecule in colorectal tumorigenesis, we
examined 52 paired normal and tumour colorectal specimens stratified by level of microsatellite
instability; 18 with high-level microsatellite instability (MSI-H) and 34 microsatellite stable (MSS).
SnoN transcript expression was quantitated by real-time PCR and analysed with respect to clinical
indicators of prognosis.
Results: Within the MSI-H subgroup, SnoN was commonly either up-regulated (6/18, 33%) or
down-regulated (7/18, 39%). A significantly different distribution of SnoN expression was observed
in MSS cancers compared with MSI-H (P ≤ 0.001). Whilst 17/34 (50%) of MSS tumours
demonstrated up-regulation, none showed down-regulated expression. Within the MSI-H
subgroup, up-regulation was significantly correlated with lack of repeat tract mutation in the
TGFβRII gene (P ≤ 0.025), suggesting that SnoN is more frequently up-regulated in the presence of
functional TGFβ signalling.
Conclusion: Together these data support the notion that SnoN has both oncogenic and tumour
suppressive properties depending on other genetic changes within the tumour, and that the MSI-H
pathway of colorectal tumorigenesis presents an excellent model for the study of these opposing
functions.
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Background
SnoN (ski-related novel gene) is a member of the highly
homologous Ski gene family [1], and can act as a repressor
of the TGF-β signalling pathway through either SnoN
homodimerisation or heterodimerisation with Ski [1-6].
This repression is mediated through binding of SnoN to
SMAD proteins, which are responsible for the propaga-
tion of signals initiated by TGF-β ligand for the transcrip-
tion of genes required for cell growth control and
differentiation [1,4,7,8]. Conversely, SnoN has also been
shown to suppress tumour growth both in a heterozygote
mouse model of SnoN inactivation [9] and in human cells
[10]. These opposing functions have led to difficulty in
interpreting the complex roles of SnoN in human malig-
nancies.
Both SnoN and Ski have been implicated in the develop-
ment of human cancers including colon [11], breast [12],
melanoma [3] and oesophageal cancers [13]. Expression
of SnoN has not previously been examined in colorectal
cancer (CRC), although a study of gene copy number sta-
tus showed that the SnoN  locus was partially or com-
pletely deleted in 55% of CRCs and amplified in 15%
[11]. Interestingly, increased copy number of Ski  was
found to be a negative prognostic indicator whilst no cor-
relation with patient outcome was observed for SnoN.
Since regulation of TGFβ signalling by SnoN involves a
combination of proteolytic degradation and transcrip-
tional up-regulation in addition to changes in copy
number, we suggest that quantification of SnoN expres-
sion may be a more informative way to assess its role in
colorectal tumour development.
Colorectal tumours stratified by level of microsatellite
instability represent two principal pathways of sporadic
colorectal tumorigenesis. The majority of sporadic CRCs
are microsatellite stable (MSS) and aneuploid. These have
been well studied but are understood to be heterogeneous
at the molecular level [14]. Cancers displaying a high level
of microsatellite instability (MSI-H) comprise approxi-
mately 15% of all sporadic CRCs, are diploid and gener-
ally have a favourable prognosis [15]. Whilst the major
mechanisms for gene inactivation in MSS cancers are
mutation and deletion, MSI-H tumours progress predom-
inantly due to repeat-tract mutation and aberrant pro-
moter hypermethylation of important target tumour
suppressor genes [16].
We have examined the frequency of altered SnoN expres-
sion in a series of CRCs stratified by MSI-status. Based on
our findings we propose that MSI-H cancers present an
excellent model for studying the dual roles of SnoN in
both tumour suppression and promotion.
Methods
Patient specimens
Fifty-two paired normal and tumour tissue specimens
were obtained in a fresh state from colectomy specimens
surgically resected at the Royal Brisbane and Women's
Hospital between 1993 and 2005. The Human Research
Ethics Committee of the Queensland Institute of Medical
Research and the Royal Brisbane and Women's Hospital
Research Ethics Committee approved this study and all
patients provided written informed consent. The standard
panel of markers (BAT25, BAT26, D5S346, D2S123 and
D17S250) recommended by a National Cancer Institute
workshop were used to determine the MSI-status of the
cancers, as previously described [17]. Patients were classi-
fied as microsatellite instability high (MSI-H) if >30% of
markers showed instability. The remainder of patients
were microsatellite stable (MSS). The patient cohort was
enriched for MSI-H tumours, but was otherwise unse-
lected. Patients with familial adenomatous polyposis
(FAP) or hereditary non-polyposis colorectal cancer
(HNPCC) were excluded from the study.
Expression analysis
Total RNA was extracted from tissue samples which had
been snap frozen in liquid nitrogen then stored at -80°C
using the QIAGEN RNeasy Midi Kit. Total RNA (5 μg) was
reverse transcribed using random hexamers and Super-
Script III Reverse Transcriptase (Invitrogen, USA). Semi-
quantitative real-time polymerase chain reaction was per-
formed using a Corbett Rotor-Gene 3000 machine (Cor-
bett Research, Australia) with the following gene specific
primers: Reference gene, β-ActinF: 5'-TCATGAAGTGT-
GACGTGGACATC-3';  β-ActinR: 5'-CAGGAGGAGCAAT-
GATCTTGATCT-3'; Gene Of Interest, SnoNF: 5'-
CACCCCAGCTACTACTTATAC-3', SnoNR: 5'-
TTGCCTCTGTCTTTGTGAGC-3') and Platinum SYBR
Green qPCR Supermix-UDG (Invitrogen, USA). Each reac-
tion contained 8 μL of qPCR mix, 5 pmol of each forward
and reverse primer and 4 μL of diluted cDNA template.
The following cycling conditions were applied: 50°C for 2
min, 95°C for 2 min, followed by 45 cycles of 95°C for 15
sec, 59°C for 15 sec, 72°C for 20 sec, 76°C of 15 sec. Data
for each cycle was acquired after the final cycling step. A
melt ramp consisting of 1°C increments from 60°C to
99°C (30 sec first step, 1 sec for subsequent steps) fol-
lowed the 45 cycles. Each reaction was carried out in
duplicate (patient samples) or triplicate (calibrator). The
relative expression of SnoN to β-Actin was calculated
using the method previously described by Pfaffl [18].
qPCR results from each set of reaction replicates varied no
more than 5% from the mean. Normalised SnoN expres-
sion values (R) for all tumours were divided by the R value
for their matched normal mucosa to indicate fold up-reg-
ulation, the inverse gave a whole number to indicate fold
down-regulation. Data was analysed based on empiricalBMC Cancer 2006, 6:252 http://www.biomedcentral.com/1471-2407/6/252
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fold differences (student's T-test) as well as number of
tumours showing greater than 2 fold up- or down-regula-
tion (Pearson's chi square). The cut-off of 2-fold was arbi-
trarily chosen as significant, based on previous reports in
the colorectal literature [19,20].
TGFβRII mutation analysis
The presence of somatic mutations in the poly(A)10 tract
of the transforming growth factor β receptor II (TGFβRII)
coding sequence was investigated in MSI-H tumours by
PCR followed by direct manual sequencing of the adeno-
sine nucleotide. Both 1-bp and 2-bp deletions are pre-
dicted to result in a truncated protein product. The PCR
consisted of a 50 μL reaction containing 250 ng template
DNA, 1.5 mM MgCl2, 0.2 mM nucleotides, 20 pmol for-
ward and reverse primers, 1X Gold Buffer and 2U Ampli-
Taq Gold (Applied Biosystems). Primers were TGFBR2f:
5'-CTTTATTCTGGAAGATGCTGC-3' and TGFBR2r: 5'-
GATGATGTTGTCATTGCACTC-3'. Following column
purification (QIAGEN) 1 μL of PCR product was sub-
jected to direct manual sequencing using the same for-
ward and reverse primers with the Ampli-Cycle cycle
sequencing kit (Perkin Elmer). The 115-bp product was
electrophoresed on a 6% denaturing polyacrylamide gel
for 75 minutes.
Clinical correlates
Disease-staging data was obtained for all patients accord-
ing to the ACPS [21] and TNM staging systems [22]. TNM
staging provided information on the extent of primary
tumour invasion (T), local lymph node spread (N) and
metastasis to a distant site (M). Patients were followed for
an average of 43 months and clinical data was recorded
for patient age, sex and tumour anatomical location.
Tumour recurrence, death due to cancer and death due to
any other cause were also noted.
Statistical analysis
Tabular data were analysed by Pearson's chi square using
Web Chi Square Calculator [23] to determine significance.
Non-parametric t-tests (Mann-Whitney) were performed
using GraphPad Prism version 4.00 for Windows [24]. P-
values less than 0.05 were considered statistically signifi-
cant.
Results
SnoN expression levels compared with MSI-status
Transcript levels of SnoN were examined in 34 MSS and 18
MSI-H tumours relative to matched normal mucosa.
There was a significantly different distribution of expres-
sion observed in MSI-H compared to MSS cancers (P <
0.01). Whilst expression varied from 9.2 fold down-regu-
lated to 38.1 fold up-regulated in MSI-H cancers, the
majority of MSS cancers showed expression higher than
matched normal mucosa levels, to a maximum of 10.5
fold (Fig. 1). Considering >2 fold expression differences as
significant, SnoN was up-regulated in 6/18 (33%) MSI-H
cancers, whilst expression was down-regulated in 7/18
(39%) tumours in this group. By contrast, within the MSS
tumour group, cancers were equally likely to demonstrate
SnoN up-regulation (17/34, 50%) as they were to show no
change in expression level (17/34, 50%) (Table 1, P <
0.001). Significance was maintained even when the cut-
off was reduced to 1.5 fold de-regulation (P < 0.001).
SnoN expression levels compared with clinical features
No significant correlations were observed between SnoN
expression levels and patient age, sex, site or ACPS stage
(Table 1). Evaluation of extent of tumour invasion (T),
local spread to lymph nodes (N) or distant metastatic
spread (M) derived from the TNM staging system did not
reveal any significant correlations. Within the MSS group,
more patients without increased SnoN expression had a
stage D tumour, as compared with those patients with
increased SnoN expression (Table 1). Of patients with a
stage A, B or C tumour, 3 had a recurrence of cancer. None
of these tumours showed increased SnoN  expression.
When these two groups were combined to indicate a poor
prognosis, there was a statistically significant association
between poor outcome and failure to elevate SnoN (Table
1, P < 0.025). There were only two stage D MSI-H
Distribution of SnoN expression in tumours stratified by MSI- status Figure 1
Distribution of SnoN expression in tumours stratified by MSI-
status. SnoN data points were determined by semi-quantita-
tive real-time PCR and are expressed as either fold up- or 
down-regulated, as compared to matched normal mucosa. 
Whilst there was a wide range of increased and decreased 
expression changes in the MSI-H subgroup, no MSS tumours 
demonstrated down-regulation greater than 2 fold.
MSI-H MSS
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tumours, neither of which showed increased SnoN expres-
sion.
TGFβRII mutation
Fifteen MSI-H tumours were assessed for repeat tract
mutation in the coding region of the TGFβRII gene (Table
2). Mutations were detected in 12/15 (80%). Interest-
ingly, three out of the six tumours demonstrating up-reg-
ulated SnoN  expression were wild-type for this usually
common mutation, whilst all nine tumours which did not
have SnoN up-regulated had a mutation of either one or
both TGFβRII alleles (P ≤ 0.025).
Discussion
SnoN is an important negative regulator of TGFβ induced
tumour suppression, and exerts an oncogenic effect by
binding to SMAD protein complexes [7,25]. Importantly,
SnoN has also been shown to suppress tumour growth in
both epithelial cell line and murine models [9,10]. To fur-
ther delineate the role of SnoN gene regulation in colorec-
tal tumours, we quantified mRNA expression in a series of
sporadic CRCs stratified by MSI-status.
Down-regulation of a gene in a significant number of
tumours compared with matched normal mucosa would
usually suggest abrogation of tumour suppressor gene
function. Strikingly, SnoN was down-regulated in 39% of
MSI-H CRCs in this study (7/18), but not in any of the 34
MSS cancers examined (P ≤ 0.001). This suggests that
SnoN  may be an important tumour suppressor gene,
exclusively in CRCs progressing via the MSI pathway of
tumorigenesis. Even when the arbitrary cut-off for signifi-
cant expression differences was reduced to only 1.5 fold,
the statistically significant association between up-regula-
tion of SnoN in MSS CRCs and down-regulation in MSI-H
CRCs was maintained (P ≤ 0.001), suggesting that even
subtle changes in SnoN gene expression levels are capable
of exerting a functional effect.
There is currently no evidence that the SnoN locus is a
direct target for down-regulation. Although repeat-tract
mutation and promoter hypermethylation are the major
mechanisms of gene disruption in MSI-H CRCs, the SnoN
transcript does not contain an extended repeat tract, nor
does the 5' region represent a typical CpG island likely to
be silenced by methylation. Whilst chromosomal instabil-
ity is a characteristic feature of most MSS cancers, locus
deletion is an uncommon mechanism for gene down-reg-
ulation in MSI-H tumours. It is more likely that SnoN is
transcriptionally down-regulated due to disruption of the
negative feedback loop involving TGFβ signalling [7].
Accumulating evidence suggests that SnoN is an impor-
tant regulator of TGFβ signalling, and acts predominantly
through binding to TGFβ signal-transducing SMAD pro-
teins [7,25]. High levels of SnoN have been shown to
inhibit TGFβ signal transduction in breast [12] and skin
cells [26]. In MSI-H tumours, mutation of TGFβRII causes
resistance to TGFβ-induced growth inhibition [27]. We
proposed that such a situation would decrease the selec-
Table 1: SnoN expression differences relative to MSI-Status and Clinical Characteristics
MSI-H MSS
SnoN Expression Level SnoN Expression Level
Total Increased No Change Decreased Total Increased No Change
Total No. Patients 18 6 5 7 34 17 17 P < 0.001Δ
Sex
Male 6 2 1 3 21 9 12
Female 12 4 4 4 13 8 5
Site
Proximal 13 3 5 5 14 8 6
Distal 5 3 0 2 20 9 11
ACPS Stage
A 5 04 1 6 33
B8 5 0 3 1 5 8 7
C 3 10 2 5 32
D 2 01 1 7 25
Recurrence of Cancer in ACPS Stage A, B or C 0 0 0 0 3 0 3 P < 0.1•
ACPS Stage D or Recurrence of Cancer in ACPS 
Stage A, B or C
2 0 1 1 10 2 8 P < 0.025
ΔSnoN expression relative to MSI-status
• SnoN expression relative to recurrence in ACPS stage A, B or C in MSS subgroup
 SnoN expression relative to the number of patients with an ACPS stage D MSS cancer, or ACPS stage A, B or C MSS cancer which recurredBMC Cancer 2006, 6:252 http://www.biomedcentral.com/1471-2407/6/252
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tion pressure to up-regulate SnoN and therefore examined
the A10  repeat tract mutation of TGFβRII  commonly
observed in MSI-H cancers [28]. We found that SnoN was
indeed up-regulated more commonly in tumours with a
wild-type receptor sequence (P ≤ 0.025), which may sup-
port a link between intact TGFβ signalling and SnoN up-
regulation.
SnoN was also up-regulated compared to matched normal
mucosa in a large number of MSS cancers (17/34, 50%),
however reduced expression was not observed for any
MSS tumour. This is discordant with the observed fre-
quencies of gene amplification (15%) and deletion (55%)
reported by Buess and colleagues [11], and highlights the
importance of examining expression levels where post-
transcriptional processing may further modulate tran-
script levels beyond the linear affect of altered copy
number. Chromosomal instability is common in MSS
cancers, and usually manifests as high rates of deletion of
chromosomal regions where a mutated tumour suppres-
sor gene is located on the remaining allele. It is possible
that the high rate of deletion observed by Buess and col-
leagues is a result of another gene target on chromosome
3q26, whilst expression of the remaining SnoN allele is
increased through compensatory transcriptional mecha-
nisms, despite hemizygous deletion.
Luo (2004) suggested that the seemingly opposing
tumour promoting and suppressing roles of SnoN may
reflect the likewise dual roles of TGFβ in tumorigenesis
[1]. It was proposed that early in tumour development
TGFβ signalling would be activated to facilitate growth
suppression. However, subsequent disruption of TGFβ
signalling later in tumorigenesis could enhance the ability
of TGFβ to promote tumour invasion and metastasis.
Therefore, abrogation of TGFβ signalling via up-regula-
tion of SnoN could result in tumours which are large but
less likely to metastasise. This is entirely consistent with
our finding of a more positive prognostic outcome in rela-
tion to cancers with increased SnoN expression. MSI is a
well-established marker for a favourable prognosis [29].
This is consistent with only 2/18 of the MSI-H tumours in
this series being ACPS stage D. Furthermore, it is interest-
ing to note that neither of these cancers showed up-regu-
lation of SnoN.
Our suggested association between failure to up-regulate
SnoN and poor patient outcome in MSS cancers may be
related to the role of SnoN in TGFβ signalling. This inter-
esting observation warrants further investigation in a
larger patient cohort which would allow correction for
tumour stage. Comprehensive studies are now necessary
to fully elucidate the connection between disrupted TGFβ
signalling and the role SnoN may play in maintaining the
balance between cell proliferation and differentiation.
Conclusion
SnoN transcript expression was commonly up-regulated
in colorectal tumours, regardless of microsatellite instabil-
ity status. Importantly, SnoN was also frequently down-
regulated specifically in microsatellite instability high
(MSI-H) colon cancers. Based on this finding, we propose
that MSI-H tumours present a unique model for examin-
ing the dual suppressive and oncogenic roles of this
important regulatory gene in colorectal tumorigenesis.
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